Inmune Bio (INMB) Other Non-Current Assets (2021 - 2026)
Inmune Bio (INMB) posted Other Non-Current Assets of $683000.0 for Q1 2026, up 14.79% sequentially from $595000.0 in Q4 2025, and up 1293.88% YoY from $49000.0 in Q1 2025.
Inmune Bio (INMB) Other Non-Current Assets (2021 - 2026) Analysis & Trends
Inmune Bio has reported Other Non-Current Assets for 6 years, with the latest figure at $683000.0 in Q1 2026.
- Quarterly Other Non-Current Assets rose 1293.88% year-over-year to $683000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $683000.0 (up 1293.88% YoY) and the FY2025 annual result came in at $595000.0, up 653.16% from the prior year.
- Other Non-Current Assets climbed to $683000.0 in Q1 2026 per INMB's latest filing, from $595000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $746000.0 in Q3 2025 and troughed at $49000.0 in Q1 2025.
- A 5-year average of $228000.0 and a median of $99000.0 in 2022 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2025 and 2026: Other Non-Current Assets plunged 53.77% in 2025, then soared 1293.88% in 2026.
- Over 5 years, Other Non-Current Assets stood at $99000.0 in 2022, then jumped by 32.32% to $131000.0 in 2023, then plunged by 39.69% to $79000.0 in 2024, then surged by 653.16% to $595000.0 in 2025, then rose by 14.79% to $683000.0 in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $683000.0, $595000.0, and $746000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - | 537,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 537,000.00 |
| Mar 31, 2026 | 683,000.00 |
| Dec 31, 2025 | 595,000.00 |
| Sep 30, 2025 | 746,000.00 |
| Jun 30, 2025 | 570,000.00 |
| Mar 31, 2025 | 49,000.00 |
| Dec 31, 2024 | 79,000.00 |
| Sep 30, 2024 | 82,000.00 |
| Jun 30, 2024 | 81,000.00 |
| Mar 31, 2024 | 106,000.00 |
| Dec 31, 2023 | 131,000.00 |
| Sep 30, 2023 | 129,000.00 |
| Jun 30, 2023 | 130,000.00 |
| Mar 31, 2023 | 99,000.00 |
| Dec 31, 2022 | 99,000.00 |
| Sep 30, 2022 | 99,000.00 |
| Jun 30, 2022 | 99,000.00 |
| Mar 31, 2022 | 99,000.00 |
| Dec 31, 2021 | 99,000.00 |
| Sep 30, 2021 | 99,000.00 |